Antitumor Effects of Sunitinib or Sorafenib in Patients With Metastatic Renal Cell Carcinoma Who Received Prior Antiangiogenic Therapy

Dvorak, 2002, Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, J Clin Oncol, 20, 4368, 10.1200/JCO.2002.10.088

Rini, 2005, Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma, J Clin Oncol, 23, 1028, 10.1200/JCO.2005.01.186

Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 1, 16, 10.1200/JCO.2005.02.2574

Motzer, 2006, Sunitinib in patients with metastatic renal cell carcinoma, JAMA, 295, 2516, 10.1001/jama.295.21.2516

Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044

Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 185, 10.1056/NEJMoa060655

Rini, 2006, Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC), J Clin Oncol, 24

Eisen, 2000, Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer, Br J Cancer, 82, 812, 10.1054/bjoc.1999.1004

Stebbing, 2001, The treatment of advanced renal cell cancer with high-dose oral thalidomide, Br J Cancer, 85, 953, 10.1054/bjoc.2001.2025

Olencki, 2006, Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma, Invest New Drugs, 24, 321, 10.1007/s10637-005-5211-z

Ridenhour, 2002, Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma, Proc Am Soc Clin Oncol, 21, 154b

Choueiri, 2006, Phase II study of lenalidomide in patients with metastatic renal cell carcinoma, Cancer, 107, 2609, 10.1002/cncr.22290

Kuwada, 2007, Drug evaluation: volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody, Curr Opin Mol Ther, 9, 92

Bukowski, 2006, Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC), J Clin Oncol, 24

Rini, 2005, AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC), J Clin Oncol, 23

Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Dham, 2007, Sequential therapy with sorafenib and sunitinib in renal cell carcinoma, J Clin Oncol, 25

Sablin, 2007, Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients, J Clin Oncol 2007, 25